anacetrapib [orch, phsu]
Cholesteryl Ester Transfer Protein [aapp, bacs]
Inhibitor [qlco]
Introduction [hlca]
Inhibition [menp]
Cholesteryl Ester Transfer Protein [aapp, bacs]
Ability [orga]
High density lipoprotein cholesterol level [lbpr]
CARDIOVASCULAR [bdsy]
Cholesteryl Ester Transfer Protein [aapp, bacs]
Inhibitor [qlco]
torcetrapib [orch]
Discontinued [fndg]
Target [ftcn]
effects [qlco]
Increased [qnco]
Mortality [qnco]
anacetrapib [orch, phsu]
APPEAR [qlco]
Exhibit [inpr]
effects [qlco]
Inhibitor [qlco]
Cholesteryl Ester Transfer Protein [aapp, bacs]
Orally [spco]
Administered [ftcn]
treatment [ftcn]
Primary hypercholesterolaemia [dsyn]
Mixed hyperlipidaemia [dsyn]
Covered [ftcn]
Covered [ftcn]
Mode [ftcn]
Action [ftcn]
Pre-clinical [qlco]
Clinical Trials [resa]
anacetrapib [orch, phsu]
Cholesteryl Ester Transfer Protein [aapp, bacs]
Inhibitor [qlco]
Article [inpr]
Understanding [menp]
PHARMACOKINETIC [resa]
pharmacodynamic [biof]
Characteristics [qlco]
anacetrapib [orch, phsu]
Insight [menp]
Efficacy [qlco]
Safety [hcpp]
Clinical Trials [resa]
anacetrapib [orch, phsu]
Dose-dependent [qnco]
elevations [spco]
High Density Lipoprotein Cholesterol [bacs, lipd]
reductions [npop]
Low density lipoprotein [aapp, bacs, lipd]
Cholesterol [bacs, strd]
anacetrapib [orch, phsu]
Apolipoprotein A-I [aapp, bacs]
Decrease [qlco]
Apo-B [aapp, bacs]
Expert Opinion [cnce]
anacetrapib [orch, phsu]
Reversible [ftcn]
Cholesteryl Ester Transfer Protein [aapp, bacs]
Inhibitor [qlco]
Able [orga]
High Density Lipoprotein Cholesterol [bacs, lipd]
Decrease [qlco]
Cholesterol, LDL [bacs, strd]
Taken [cnce]
Combination [qlco]
Statin [orch, phsu]
Safety [hcpp]
Tolerability Study [resa]
Reported [inpr]
Date [tmco]
promise [idcn]
Phase III Trials [resa]
investigating [ftcn]
Efficacy [qlco]
anacetrapib [orch, phsu]
Prevention [topp]
coronary [bpoc]
Events [evnt]
Patients [podg]
atherosclerotic [ftcn]
Cardiovascular Disorders [dsyn]
Interest [menp]
